Last Updated : May 8, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Remsima | infliximab | Crohn’s disease | Active | |||
| Remsima | infliximab | Ulcerative Colitis | Active | |||
| Bimzelx | bimekizumab | Ankylosing spondylitis | Active |
Last Updated : May 8, 2024